ASAnne Schlegtendal

Anne Schlegtendal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne Schlegtendal has a total of 334 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TasTY: Development and evaluation of a taste test for quantifying taste sensitivity among preschool children—test–retest reliability, application, and comparison between children with and without prior SARS-CoV-2 infection

    by Johannes Weißenfeld, Christoph Maier, Christine H. Meyer-Frießem, Anna Teresa Hoffmann, Thomas Lücke, Anne Schlegtendal

    Taste dysfunction gained attention during the coronavirus disease 2019 (COVID-19) pandemic; however, validated objective tests for preschool children remain limited. We aimed to develop a feasible, reliable test quantifying taste sensitivity among children aged 3–6 years and to compare performance between children with and without prior SARS-CoV-2 infection. We included 68 symptom-free children (median age 5.1 years; interquartile range (IQR) 3.9–5.9): 36 without known SARS-CoV-2 infection (control group, CG) and 32 with confirmed prior infection (SARS-CoV-2 infection group, C19-G), tested 79 days after infection (median; IQR 56–112). Children completed a self-developed Taste Test for Young Children (TasTY), a double-blind, playful two-alternative forced-choice test with 10 samples in randomized order (sweet, sour, and salty at three concentrations each; water served as a control). Twenty controls were retested a median of 62 days later (IQR 38–64). Outcomes were total score (0–10), feasibility, task comprehension, and test–retest reliability, assessed using the intraclass correlation coefficient (ICC), standard error of measurement (SEM), and smallest real difference (SRD). Feasibility was high (3% dropout), and 89.4% correctly classified water. Total score test–retest reliability was good (ICC = 0.73; pooled SEM = 0.76; SRD = 2.11). Total scores were similar between CG and C19-G (8.37 ± 1.5 vs. 8.19 ± 1.5; p = 0.63). Descriptively, three-year-olds ( n = 17) had lower, more variable scores. Conclusion : TasTY provides an age-appropriate, reliable, objective method for quantifying taste sensitivity among preschoolers, supporting standardized group comparisons and longitudinal assessment. What is Known: • COVID-19 increased awareness of taste dysfunction; however, evidence among young children relies mainly on surveys and parental reports. • Objective taste tests for preschool children remain limited. What is New: • TasTY is a feasible, standardized, and objective test for quantifying taste sensitivity among children aged 3–6 years and goes beyond parental and subjective reports. • Its standardized 0–10 score showed good test–retest reliability and may support group comparisons and longitudinal assessment of preschool children with taste-related conditions.

  • Antibiotic Therapy for Pseudomonas aeruginosa in Primary Ciliary Dyskinesia: Effectiveness and Key Influencing Factors

    by Anne Schlegtendal, Vanessa Fein, Christoph Maier, Folke Brinkmann, Thomas Lücke

    Background: Infections with Pseudomonas aeruginosa (PsA) are suspected of accelerating lung-disease progression in patients with Primary Ciliary Dyskinesia (pPCD). But only one study has analysed the efficacy of antibiotic therapy (AT) for early PsA infection in pPCD, and no therapeutic guidelines exist. Objective: To assess the efficacy of AT for PsA infections in pPCD in a real-life setting considering potential influencing factors. Methods: We analysed all pPCD (children and adults) treated with AT for initial and recurrent PsA infection at the University Children’s Hospital Bochum between 2010-2025. AT, following cystic fibrosis protocols, included mainly inhaled tobramycin or colistin with oral ciprofloxacin or intravenous combination therapy guided by the antimicrobial susceptibility report. Chronic infection was defined as detection of PsA in more than 50% of samples collected over the past year. Short- and long-term treatment success was defined as the absence of PsA at 6, 12, and 36 months. Patient characteristics, lung function, influencing factors (e.g. PsA detection frequency, chronic colonization, resistance development, exacerbation rate), and side effects of therapy were documented. Results: Of 82 PsA positive tests in 22 pPCD, 33 were conducted during periods of chronic colonization in 9 pPCD. Of the remaining 49 tests, 35 (71.4%), 29 (59.2%), and 13 (26.5%) were negative at 6, 12, and 36 months post-treatment, respectively. In 4 out of 5 chronically colonised pPCD, PsA was successfully re-eradicated. Conclusion: AT for PsA infections in pPCD demonstrates high efficacy and frequently achieves a durable response, even in recurrent or chronic cases. Ongoing data analysis, focusing on various influencing factors, will be presented at the conference.

  • Open Access

    More than a feeling? Impact of face masks on cardiorespiratory parameters and microclimate under the mask in school-aged children

    by Eike-Maximilian Marek, Adriana Talarico, Vera van Kampen, Thomas Behrens, Birger Jettkant, Susann Widmer, Frank Hoffmeyer, Nelly Otte, Anna Hoffmann, Anne Schlegtendal, et al.

  • Open Access

    “I Can Taste It, But Sometimes It’s Disgusting” Cross-sectional Study on the Influence of SARS-CoV-2 Infections, Both Acute and Postinfection, in Comparison to Other Respiratory Infections on Taste and Smell Perception

    by Claire Mallon, Folke Brinkmann, Anne Schlegtendal, Christoph Maier, Thomas Lücke, Anna Teresa Hoffmann

    Background: Subjective smell and taste disorders were frequently reported during and after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (SCI), but mostly investigated by interviews/questionnaires. Methods: We examined from 07/2021 to 10/2022 objective (U-Sniff/Taste Strips) and subjective (questionnaire-based) impairment in children with (1) acute SCI (AC; n = 30) and other upper respiratory tract infection (n = 34), (2) children with (PI+; n = 28)/without (PI−; n = 13) remaining symptoms ≥12 weeks after SCI and (3) as control 18 noninfected children. Children with acute infections were examined blinded regarding the results of their SARS-CoV-2 polymerase chain reaction. Statistics: X², F test, Kruskal–Wallis, P < 0.05. Results: Abnormal test results occurred in up to a fifth of children. Severe hyposmia was detected in 17% of children with upper respiratory tract infection and 21% in PI+, severe hypogeusia was mostly in AC children (18%), followed by both postinfection groups (PI+ 12%, PI− 10%). Subjective smell impairment was significantly more frequent in PI+ (32% vs. ≤7% in all other groups), similar for taste (PI+ = 29%, AC = 14% vs. ≤10% in all other groups). Children in PI+ and PI− reported significantly more negative sensory affects (“tastes/smells disgusting,” 14% each), without correlation with abnormal test results. Conclusion: In the omicron era, hyposmia and hypogeusia are not pathognomonic for acute SARS-CoV-2 infections. In a subgroup, SARS-CoV-2 can cause long-lasting taste and smell impairment, mostly aversive changes, which are not detected by the validated tests. It is therefore essentially necessary to apply objective and subjective methods at the same time to improve the detection of hyposmia and hypogeusia in children.


  • Open Access

    Taste and Smell Disorders in Children and Young Adults With Cystic Fibrosis and Primary Ciliary Dyskinesia—A Prospective Comparative Study

    by Lea Christiane Beermann, Lisa Sophie Demski, Lynn Eitner, Stefanie Dillenhöfer, Anne Schlegtendal, Claire Mallon, Folke Brinkmann, Christoph Maier, Thomas Lücke, Anna Teresa Hoffmann

    Background: In cystic fibrosis (CF), the defect of the CF transmembrane conductance regulator (CFTR) can also affect sensory nerve cell function, as recently demonstrated in animal models. The aim of this prospective cohort study was to investigate whether taste and smell disorders in CF correlate with persistent CFTR dysfunction detectable by iontophoresis or rather with inflammation or lung function. Participants with primary ciliary dyskinesia (PCD) and controls without pulmonary disease served as comparators. Methods: In 65 participants (age median 19 years IQR [12−26]; CF n = 23, PCD n = 22, controls n = 20) at the University Children´s Hospital Bochum, we measured taste (salty, sweet, sour, bitter) at four concentrations (“Taste‐Strips,” score 0−16, hypogeusia age‐adjusted < 8/< 9/< 9.9/< 10 points) and smell (“U‐Sniff”‐test, score 0−12, reduced odor identification performance < 8 points), pilocarpine iontophoresis, spirometry, inflammatory markers (e.g., CRP) and subjective chemosensory impairment. Statistics: Chi²/Fisher's‐exact, Mann−Whitney‐ U , Kruskal−Wallis, linear regression; p < 0.05. Results: Hypogeusia occurred only in CF (17.4%). Particularly misidentification of the taste “salty” occurred significantly more frequently in CF (34.8% vs. PCD 19.3% and controls 17.5%), especially in the CF subgroup with elevated sweat chloride ≥ 60 mmol/l. Reduced odor identification performance was significantly more common in PCD (30% vs. CF 4%). Chemosensory disorders were not related to current lung function or inflammation. Conclusion: Taste disorders in CF are mostly attributed to difficulties tasting salty and are associated with elevated sweat chloride, probably caused by increased salivary salt following CFTR dysfunction in salivary glands rather than in the nerve cells. Smell disorders, however, remain a significant issue, particularly in PCD.


  • Open Access

    Randomized Cross‐Over Analysis of the Influence of Nitrogen Multiple Breath Washout on Spirometry in Monitoring Lung Function in Patients With Cystic Fibrosis and Primary Ciliary Dyskinesia

    by Anna Charlotte Schoop, Robin Denz, Christoph Maier, Folke Brinkmann, Thomas Lücke, Anne Schlegtendal

    Background: When monitoring lung function in patients with Cystic Fibrosis (pwCF) and Primary Ciliary Dyskinesia (pwPCD), nitrogen multiple breath washout (N 2 MBW) is usually performed before spirometry to prevent forced expiratory maneuvers from altering N 2 MBW results. The N 2 MBW may affect spirometry if cooperation decreases after a long period of examination or due to prolonged oxygen inhalation. The equivalence of these concepts has never been investigated in a randomized cross‐over trial. We hypothesized that the order of pulmonary function tests (PFTs) would not influence the z ‐score FEV 1 . Methods: A total of 47 clinically stable outpatients (36 pwCF, 11 pwPCD; 16.7 ± 8.1 years) were randomized into two groups. Each patient underwent N 2 MBW and spirometry at two consecutive visits (median interval 104 days): Group I: Spirometry followed by N 2 MBW (A), reversed order at the second visit (B), Group II reversed (B→A). Statistics: For the equivalence test, a change in z ‐score FEV1 (primary endpoint) ±0.2 and lung clearance index (LCI 2.5 , secondary endpoint) ±15% was not considered relevant; therefore, changes outside this range were considered an intervention effect in the linear mixed model ( p < 0.05). Results: There was a significant deterioration in z ‐score FEV1 between the two appointments (period effect: −0.177; p = 0.012). The intervention effect and 95% confidence interval were within the equivalence range in both groups ( z ‐score FEV1: 0.039; −0.0765 to 0.1539, LCI 2.5 : −0.082; −0.3691 to 0.2054). Discussion: In our cohort the order of PFTs has no influence on the results suggesting that a greater flexibility in practice is possible without the risk of falsifying results. Trial Registration: German Clinical Trials Register (No. DRKS00027473).


  • Open Access

    Ex Vivo Osteoclastogenesis from Peripheral Blood Mononuclear Cells Is Unchanged in Adults with Phenylketonuria, Regardless of Dietary Compliance

    by Beatrice Hanusch, Anne Schlegtendal, Thomas Lücke, Kathrin Sinningen

    Pathogenic variants in the phenylalanine hydroxylase gene can result in phenylalanine (Phe) accumulation leading to phenylketonuria (PKU; OMIM #261600), a metabolic disease diagnosed in newborn screening. Early treatment with a Phe-restricted diet prevents severe mental retardation. Next to several other health complaints, patients with PKU present with low bone mineral density (BMD) more often than the general population. The etiology of the phenotype is not yet fully understood, and current research focuses on improving special medical foods and changes in osteoclasts (OC) and osteoblasts. Analysis of osteoclastic and oxidative stress control gene expression next to the simple number of OC developing from peripheral blood mononucleated cells (PBMCs) in association with dietary compliance and BMD was therefore part of our analysis. PBMCs were obtained from 17 adults with PKU and 17 age- and sex-matched controls on the same day. PBMCs were differentiated into osteoclasts (OC, Trap-positive multi-nucleated cells (≥3 nuclei)) for 14 days by adding human macrophage colony-stimulating factor (MCSF) and receptor activator of NF-κB Ligand (RANKL). Subsequently, quantitative real-time PCR was performed on OC function and oxidative stress control. Data on dietary compliance during the previous 12 months and 5 years and BMD were collected. PBMCs from adults with PKU and controls were differentiated into comparable numbers of OC (PKU: 53 [17–87] vs. controls: 39 [19–52], p = 0.381) without differences in mRNA expression of genes related to OC function and oxidative stress control. Dietary compliance in short-term and mid-term was not associated with OC number or mRNA expression, but CTSK negatively correlated with BMD T-Score in the hips of adults with PKU (Spearman r = −0.518, p = 0.040). Osteoclastogenesis was not changed in adult patients with PKU, nor were most mRNA expressions of OC marker genes or those of oxidative stress control. However, 44% of patients presented with BMD below −1 in their hips, and the OC of these tended to express higher CTSK (above −1: 0.2 [0.2–0.8] vs. below −1: 0.9 [0.6–3.4], p = 0.055). Thus, alternative regulatory mechanisms of OC activity may play a role in the development of low BMD in patients with PKU.


  • Open Access

    Long‐Term Pulmonary Sequelae 5–14 Years After Protracted Bacterial Bronchitis in Early Childhood

    by Jan Hermann, Karen Brückner, Cordula Koerner‐Rettberg, Stefanie Dillenhöfer, Folke Brinkmann, Christoph Maier, Christoph M. Heyer, Anne Schlegtendal

    Background: There is little information about long‐term changes in pulmonary function tests (PFTs) many years after protracted bacterial bronchitis (PBB), the most common cause of chronic wet cough in early childhood. Methods: Of 200 consecutively recruited children with a previously proven diagnosis of PBB 62 (12.2 years, female 48%) were interviewed after 7.7 (5.4–14.7) years about their previous and current symptoms and pulmonary function tests (PFTs: spirometry, body plethysmography, nitrogen multi‐breath washout, exhaled nitric oxide and nasal nitric oxide) were performed. Children with persistent symptoms were offered lung imaging. Results: 11 (17.7%) patients suffered from chronic or recurring wet cough years after their first PBB episode. 15 (24.19%) had at least one abnormal spirometry parameter. FEV1 was abnormal in eight of 62 (12.9%), LCI 2.5% in seven of 56 (12.5%), FVC in 12 of 62 (19.35%) and FEV1/FVC in five of 62 (8.06%) cases. PFT did not differ between children with and without wet cough. Lung MRI/CT demonstrate in four of nine cases abnormalities of the bronchial walls, including one with incipient bronchiectasis. Conclusion: After PBB in early childhood, a significant proportion of children suffer from respiratory symptoms many years later, some have an objectively reduced lung function and structural changes of the bronchial wall despite adequate initial therapy. Wet cough alone seems not to be a sensitive clinical predictor. Due to the retrospective study design, we cannot proof any causal relationship. However, to detect late bronchopulmonary sequelae, continuous follow‐up of these children should become mandatory.


  • Mucoid Staphylococcus aureus : A Clinical Trial of Its Prevalence and Association with Lung Function in People with Cystic Fibrosis

    by Christine H. Rumpf, Timo Janssen, Robert Jonathan Hait, Karin Romme, Clemens Decker, Janne Peters, Corinna Czowalla, Susanne Deiwick, Dennis Görlich, Angelika Dübbers, et al.

    Rationale: The mucoid phenotype of Staphylococcus aureus is caused by adaptation. Excessive biofilm formation associated with a protective effect for mucoid S. aureus was observed in isolates from respiratory samples of people with cystic fibrosis (pwCF). Objectives: There is little knowledge about the prevalence of mucoid S. aureus in pwCF and a potential association with CF lung disease. Methods: A prospective multicenter study was conducted (cross-sectional and longitudinal). Specimens and case report forms were sent to the central study laboratory for characterization of S. aureus and analysis of clinical parameters. Measurements and Main Results: In the cross-sectional study, in 41 (9.1%) of 451 S. aureus–positive pwCF from 13 CF centers, mucoid S. aureus was cultured. In the longitudinal study, the distribution of CFTR genotypes and the number of pwCF with highly effective modulator therapy and coinfection with Pseudomonas aeruginosa were equivalent in the mucoid group (35 pwCF) versus the control group (only nonmucoid S. aureus; 36 pwCF). Although lung function did not differ between groups as a whole, a subgroup analysis revealed significantly worse lung function for female pwCF with mucoid S. aureus as well as for pwCF if P. aeruginosa coinfection was excluded. Conclusions: In the era of highly effective modulator therapy, worse lung function was associated with female and P. aeruginosa–negative pwCF with mucoid S. aureus compared with pwCF with only nonmucoid S. aureus. Therefore, appropriate culture conditions should be established to detect mucoid S. aureus. Further investigations are needed to elucidate the relationship between mucoid S. aureus and CF lung disease. Clinical trial registered with www.clinicaltrials.gov (NCT04171583).


  • Open Access

    Natural variability of lung function in primary ciliary dyskinesia: longitudinal analysis from the PROVALF-PCD cohort

    by Kewei Zhang, Avni Kant, Mieke Boon, Melissa Borrelli, Carolina Constant, Silvia Castillo Corullon, Renato Cutrera, Stefanie Dillenhöfer, Sanem Eryılmaz Polat, Ela Eralp, et al.

    Background: The extent to which changes in lung function are due to natural variability in patients with primary ciliary dyskinesia (PCD) is unknown. We aimed to assess intra-individual variability in forced expiratory volume in 1 s (FEV1) derived from spirometry to define the extent to which the observed changes were due to test variability in clinically stable PCD patients.Methods: PROVALF-PCD (Prospective Observational Multicentre Study on Variability of Lung Function in Stable PCD Patients) was a large international prospective cohort conducted in 2017–2019. We included patients aged ≥5 years who were clinically stable at two or more consecutive visits and provided spirometry-derived lung function measurements. To calculate the upper limit of normal (ULN), we fitted an unadjusted multilevel mixed-effect model, and to determine the absolute change in FEV1z-scores, we calculated the coefficient of repeatability (CR). We performed sensitivity analyses by stratifying relative change by age (adultsversuschildren), number of measurements (at least four), and time between measurements (25% between visits in stable PCD patients lie beyond the expected test variability and therefore could be considered physiologically relevant. These findings inform the selection of end-points for pulmonary intervention trials in PCD, as they suggest that FEV1is not a sensitive test for monitoring lung health in PCD.